Literature DB >> 7748039

Prolongation of skin allografts by recombinant tumor necrosis factor and interleukin-1.

G L Parenteau1, G M Doherty, G R Peplinski, K Tsung, J A Norton.   

Abstract

OBJECTIVE: The hypothesis is that systemic administration of recombinant tumor necrosis factor-alpha (TNF-alpha) and/or recombinant interleukin-1 alpha (IL-1 alpha) can decrease the rejection of a skin allograft. SUMMARY BACKGROUND DATA: Tumor necrosis factor and IL-1 are pluripotent cytokine hormones that are central to the host immunologic response to foreign substances. Cytokine effects and toxicity may be reduced by systemic administration of recombinant cytokines. The authors previously have demonstrated that pretreatment with cytokines such as IL-1 or TNF can reduce the lethality of endotoxin (lipopolysaccharide), gram-negative sepsis, cancer cachexia, and oxygen toxicity.
METHODS: Skin grafts from the tails of Balb/c mice were placed on the backs of C57Bl/6 mice. Mice were treated with daily intraperitoneal saline, recombinant m-TNF (Genentech, South San Francisco, CA) or h-IL-1 (Hoffman LaRoche, Nutley, NJ) from postgraft day 1 to postgraft day 28. Tumor necrosis factor and IL-1 high doses were chosen because they protected mice from the lethality of lipopolysaccharide. Animals were examined daily for toxicity and graft rejection. Graft survival was plotted in a Kaplan-Meier plot and analyzed by the log-rank test. Comparison of proportions was done using the Fisher's exact test.
RESULTS: Either TNF or IL-1 alone significantly prolonged skin graft survival compared with saline control. Furthermore, the combination of TNF and IL-1 prolonged skin graft survival longer than either cytokine alone. Mice on the highest dose TNF and IL-1 combination did not reject skin grafts during the 28-day treatment period. Significant toxicity was associated with cytokine treatment. Similar significant proportions of death occurred with IL-1 alone and the highest combination of TNF and IL-1.
CONCLUSION: Both TNF and IL-1 can be effective as suppressors of skin allograft rejection in mice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7748039      PMCID: PMC1234642          DOI: 10.1097/00000658-199505000-00015

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  24 in total

1.  Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis.

Authors:  C Wanidworanun; W Strober
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

2.  Induction of plasma inhibitors of interleukin 1 and TNF-alpha activity by endotoxin administration to normal humans.

Authors:  G A Spinas; D Bloesch; M T Kaufmann; U Keller; J M Dayer
Journal:  Am J Physiol       Date:  1990-11

3.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

4.  The role of tumor necrosis factor in allograft rejection. II. Evidence that antibody therapy against tumor necrosis factor-alpha and lymphotoxin enhances cardiac allograft survival in rats.

Authors:  D K Imagawa; J M Millis; K M Olthoff; P Seu; R A Dempsey; J Hart; P I Terasaki; E M Wasef; R W Busuttil
Journal:  Transplantation       Date:  1990-08       Impact factor: 4.939

5.  Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism.

Authors:  G H Wong; D V Goeddel
Journal:  Science       Date:  1988-11-11       Impact factor: 47.728

6.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

7.  Prolonged survival of tumor-bearing rats with repetitive low-dose recombinant tumor necrosis factor.

Authors:  B C Sheppard; D Venzon; D L Fraker; H N Langstein; J C Jensen; J A Norton
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

8.  Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor.

Authors:  B C Sheppard; D L Fraker; J A Norton
Journal:  Surgery       Date:  1989-08       Impact factor: 3.982

9.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

Authors:  S Okusawa; J A Gelfand; T Ikejima; R J Connolly; C A Dinarello
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

10.  Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity.

Authors:  D L Fraker; M C Stovroff; M J Merino; J A Norton
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.